Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · IEX Real-Time Price · USD
46.61
-1.07 (-2.24%)
At close: Jul 19, 2024, 4:00 PM
45.68
-0.93 (-2.00%)
Pre-market: Jul 22, 2024, 6:18 AM EDT
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $29.40M in the twelve months ending March 31, 2024, with 54.61% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $8.19M with 46.00% year-over-year growth. In the year 2023, Agios Pharmaceuticals had annual revenue of $26.82M with 88.36% growth.
Revenue (ttm)
$29.40M
Revenue Growth
+54.61%
P/S Ratio
90.00
Revenue / Employee
$76,174
Employees
386
Market Cap
2.65B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
Dec 31, 2022 | 14.24M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
Dec 31, 2011 | 21.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.97B |
Astrana Health | 1.45B |
Progyny | 1.11B |
PTC Therapeutics | 927.56M |
Certara | 360.69M |
Kymera Therapeutics | 79.41M |
SpringWorks Therapeutics | 26.45M |
Geron | 520.00K |
AGIO News
- 4 days ago - Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024 - GlobeNewsWire
- 7 weeks ago - Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study - Reuters
- 7 weeks ago - Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia - GlobeNewsWire
- 7 weeks ago - Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress - GlobeNewsWire
- 2 months ago - Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 - GlobeNewsWire
- 2 months ago - Agios Reports Business Highlights and First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 - GlobeNewsWire